Roivant Sciences Ltd. SEC filings ROIV
Roivant Sciences Ltd. has 995 filings in SEC EDGAR's recent list, going back to Mar 16, 2015. Its latest annual report, Form ARS, was filed on Jul 29, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (regulation fd disclosure). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 6, 2023 | — |
| CORRESP | Letter to the SEC | Oct 4, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 4, 2023 | — |
| 25-NSE | Delisting notice | Sep 1, 2023 | — |
| EFFECT | Filing | Oct 3, 2022 | — |
| EFFECT | Filing | Oct 3, 2022 | — |
| EFFECT | Filing | Oct 3, 2022 | — |
| EFFECT | Filing | Oct 3, 2022 | — |
| EFFECT | Filing | Aug 2, 2022 | — |
| EFFECT | Filing | Mar 31, 2022 | — |
| CORRESP | Letter to the SEC | Mar 28, 2022 | — |
| CORRESP | Letter to the SEC | Feb 28, 2022 | — |
| CORRESP | Letter to the SEC | Feb 24, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2022 | — |
| EFFECT | Filing | Jan 4, 2022 | — |
| CORRESP | Letter to the SEC | Dec 30, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2021 | — |
| EFFECT | Filing | Nov 9, 2021 | — |
| CORRESP | Letter to the SEC | Nov 5, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2021 | — |
| CERT | Filing | Oct 1, 2021 | — |
| 8-A12B/A | Filing | Sep 30, 2021 | — |
| 8-A12B | Filing | Sep 3, 2021 | — |
| EFFECT | Filing | Aug 10, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 10, 2021 | — |
| CORRESP | Letter to the SEC | Aug 6, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| 425 | Filing | Aug 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 29, 2021 | — |
| 425 | Form 8-k | Jul 22, 2021 | — |
| CORRESP | Letter to the SEC | Jul 22, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2021 | — |
| 425 | Form 8-k | Jul 1, 2021 | — |
| CORRESP | Letter to the SEC | Jun 30, 2021 | — |
| 425 | Filing | Jun 25, 2021 | — |
| 425 | Form 8-k | Jun 21, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 17, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2021 | — |
| 425 | Filing | Jun 9, 2021 | — |
| 425 | Filing | Jun 9, 2021 | — |
| 425 | Form 8-k | May 17, 2021 | — |
| 425 | Form 425 | May 3, 2021 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ROIV (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Bermuda
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1635088
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.